U.S. markets closed

Axsome Therapeutics, Inc. (AXSM)

NasdaqGM - NasdaqGM Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
79.80+0.63 (+0.80%)
Al cierre: 04:00PM EDT
79.96 +0.16 (+0.20%)
Fuera de horario: 06:29PM EDT

Axsome Therapeutics, Inc.

One World Trade Center
22nd Floor
New York, NY 10007
United States
212 332 3241
https://www.axsome.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo545

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Herriot Tabuteau M.D.Founder, Chairman, CEO & President1.32MN/D1968
Mr. Nick Pizzie CPA, M.B.A.Chief Financial Officer732.94kN/D1975
Mr. Mark L. JacobsonCOO & Secretary784.66kN/D1983
Mr. Hunter Murdock Esq.General Counsel & Secretary735.39kN/D1980
Dr. Amanda Jones Pharm.D.Senior Vice President of Clinical DevelopmentN/DN/D1983
Ms. Lori Englebert M.B.A.Executive Vice President of Commercial & Business DevelopmentN/DN/D1978
Joseph Debrah-Afful CPA, M.B.A.Director of FinanceN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Gestión corporativa

La calificación ISS Governance QuickScore de Axsome Therapeutics, Inc. a partir del 1 de marzo de 2024 es 8. Las puntuaciones principales son Auditoría: 8; Junta: 8; Derechos del accionista: 8; Compensación: 8.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.